- Home
- NAMS
as 12-20-2024 4:00pm EST
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
| Founded: | 2019 | Country: | Netherlands |
| Employees: | N/A | City: | NARRDEN |
| Market Cap: | 1.7B | IPO Year: | N/A |
| Target Price: | $36.20 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.50 - $27.29 | Next Earning Date: | 02-06-2025 |
| Revenue: | $33,594,000 | Revenue Growth: | 78.77% |
| Revenue Growth (this year): | 129.49% | Revenue Growth (next year): | -67.71% |
Latest NewAmsterdam Pharma Company N.V. News
NAMS Breaking Stock News: Dive into NAMS Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
GlobeNewswire
10 days ago
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Investor's Business Daily
10 days ago
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
Investor's Business Daily
11 days ago
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug
GlobeNewswire
11 days ago
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
GlobeNewswire
12 days ago
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
GlobeNewswire
15 days ago
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
a month ago
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results
Compare NAMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAMS NewAmsterdam Pharma Company N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.